LLY

1,071.5

+0.34%↑

JNJ

205.71

-0.59%↓

ABBV

229.61

+0.74%↑

UNH

324.8

-0.71%↓

AZN

92.23

+0.53%↑

LLY

1,071.5

+0.34%↑

JNJ

205.71

-0.59%↓

ABBV

229.61

+0.74%↑

UNH

324.8

-0.71%↓

AZN

92.23

+0.53%↑

LLY

1,071.5

+0.34%↑

JNJ

205.71

-0.59%↓

ABBV

229.61

+0.74%↑

UNH

324.8

-0.71%↓

AZN

92.23

+0.53%↑

LLY

1,071.5

+0.34%↑

JNJ

205.71

-0.59%↓

ABBV

229.61

+0.74%↑

UNH

324.8

-0.71%↓

AZN

92.23

+0.53%↑

LLY

1,071.5

+0.34%↑

JNJ

205.71

-0.59%↓

ABBV

229.61

+0.74%↑

UNH

324.8

-0.71%↓

AZN

92.23

+0.53%↑

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Avatud

0.32

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.32

Max

0.32

Põhinäitajad
By Trading Economics
Sissetulek	6.8M -8.1M
Müük	33M 72M
Aktsiakasum	-0.04
Kasumimarginaal	-11.242
Töötajad	105
EBITDA	6.7M -5.4M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	19. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-4.9M 86M
Eelmine avamishind	0.32
Eelmine sulgemishind	0.32

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. dets 2025, 23:54 UTC

Suurimad hinnamuutused turgudel

Novo Nordisk ADRs Gain on FDA Approval of First GLP-1 in Pill Form

22. dets 2025, 19:08 UTC

Omandamised, ülevõtmised, äriostud

Correction to Alphabet to Buy Intersect Article

22. dets 2025, 17:21 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Buy Intersect for $4.75 Billion as AI-Investment Plans Grow -- Update

22. dets 2025, 16:46 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Buy Intersect for $4.75 Billion in Cash

22. dets 2025, 23:50 UTC

Market Talk

Nikkei May Decline as Yen Rebounds -- Market Talk

22. dets 2025, 23:42 UTC

Market Talk

Gold Hits Record High Amid Rising Geopolitical Risks -- Market Talk

22. dets 2025, 22:31 UTC

Tulu

Zhejiang Sanhua Intelligent Controls: Higher Demand for Air-Conditioning Components Supported Results >002050.SZ

22. dets 2025, 22:31 UTC

Tulu

Zhejiang Sanhua Intelligent Controls: Higher Demand for Refrigeration Supported Results >002050.SZ

22. dets 2025, 22:30 UTC

Tulu

Zhejiang Sanhua Intelligent Controls Sees 2025 Net CNY3.87B, Up 25% on Year >002050.SZ

22. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. dets 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

22. dets 2025, 21:37 UTC

Omandamised, ülevõtmised, äriostud

Capricorn: Project Is Contiguous to Capricorn's Golden Range, Fields Find Tenure

22. dets 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Capricorn to Pay A$500,000 Cash, A$4M in New Shares

22. dets 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Capricorn to Acquire Prospective Package From Tempest Minerals

22. dets 2025, 21:35 UTC

Omandamised, ülevõtmised, äriostud

Capricorn Metals to Buy Yalgoo Project Tenement Package for A$4.5M

22. dets 2025, 20:54 UTC

Omandamised, ülevõtmised, äriostud

Middle West Partners Buys Paul Stuart From Mitsui & Co.

22. dets 2025, 20:52 UTC

Omandamised, ülevõtmised, äriostud

HCL Technologies: HCLSoftware to Acquire Jaspersoft From Cloud Software Group >532281.BY

22. dets 2025, 20:09 UTC

Market Talk

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

22. dets 2025, 19:56 UTC

Market Talk

Crude Gains as U.S. Increases Actions Against Venezuela -- Market Talk

22. dets 2025, 19:49 UTC

Omandamised, ülevõtmised, äriostud

A Topsy-Turvy Year for Oracle and the Ellisons Will Bleed into 2026 -- Barrons.com

22. dets 2025, 19:23 UTC

Market Talk

Mexico's Inflation Seen Easing in Early December -- Market Talk

22. dets 2025, 19:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. dets 2025, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

22. dets 2025, 19:02 UTC

Market Talk

Precious Metals Climb to New Heights -- Market Talk

22. dets 2025, 18:45 UTC

Market Talk

Canadian Trade-Exposed Industries At Forefront of Job Weakness -- Market Talk

22. dets 2025, 18:30 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Intersect Selling Portion of Assets as Part of Alphabet Deal -- Market Talk

22. dets 2025, 18:23 UTC

Omandamised, ülevõtmised, äriostud

What Yogi Berra Would Say About the Talks to Take Over Warner Bros. Discovery -- Barrons.com

22. dets 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

22. dets 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

22. dets 2025, 17:06 UTC

Omandamised, ülevõtmised, äriostud

Alphabet to Buy Intersect for $4.75B as AI-Investment Plans Grow -- Update

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.